Parexel, a clinical research organisation (CRO) offering comprehensive Phase I to IV clinical development services, has entered into a strategic alliance with the Japanese Foundation for Cancer Research (JFCR) to expedite access to oncology clinical trials in Japan.
Under the alliance, JFCR will become a valued member of Parexel’s Global Site Alliance network, designated as a preferred site for conducting oncology clinical trials. This collaboration will enhance opportunities for Japanese patients to actively participate in cancer research initiatives.
Parexel intends to capitalise on JFCR’s specialised knowledge to assist sponsors in crafting protocols that align seamlessly with Japan’s established standards of care and regulatory approval processes.
The partnership is anticipated to streamline patient recruitment and accelerate the initiation of clinical studies in the field of oncology.
Parexel corporate vice president and general manager of Japan Shigehiro Miki said: “Consistent with global trends, the incidence of cancer is expected to increase in Japan.
“We look forward to JFCR joining Parexel’s Site Alliance Network and working together to eliminate barriers and increase the access of potentially life-changing treatments to Japanese patients.”
With experience spanning more than 115 years, JFCR is said to be Japan’s first and largest medical organisation dedicated to cancer care. The organisation is known for its cross-functional, holistic cancer centre, latest research facilities and extensive number of patients under their care.
JFCR’s therapeutic expertise in combination with Parexel’s clinical research experience will enable both organisations to efficiently recruit Japanese patients often underrepresented in oncology research while expanding cancer care options in Japan.
Parexel’s Site Alliance Network is designed to provide a strategic, site solutions approach to address critical challenges in the clinical trial pathway, recruit patients more efficiently and expand clinical trial opportunities to investigators and patients globally.
The network consists of more than 480+ sites representing approximately 21,000 investigators worldwide.
Parexel’s strategic alliance agreement with JFCR is an extension of its patients-first focus and efforts to drive clinical innovation in key therapeutic areas, such as oncology, in the Asia/Pacific region.
Parexel maintains relationships with other leading alliance sites in the region, including Kyoto University Hospital, Osaka International Cancer Institute, Beijing Illness Challenge Foundation and the Cancer Hospital Chinese Academy of Medical Sciences.
